Clinical Trial Detail

NCT ID NCT02296684
Title Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

hypopharynx cancer

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

Therapies

Pembrolizumab

Cisplatin

Age Groups: adult

No variant requirements are available.